Slide 1: Q3/YTD 2024 Results
Q3/YTD 2024 RESULTS OLIVIER RIGAUD (CEO) PETER KAZIUS (CFO) 29/10/2024
Slide 2: YTD 2024 Highlights
Q3/YTD 2024 RESULTS YTD 2024 Highlights • Accelerated organic sales growth Volume/Mix* • Volume/Mix +6.1% & Pricing -3.5% +6.1% (YTD) • Continued operations (IFRS 5): Adjusted EBITDA € 135.7 million (Q3: € 49.6 million) +11.1% (Q3) • Health & Nutrition: Double-digit-growth in sales and Adjusted EBIT
Slide 3: Sales and Adjusted EBITDA: YTD/Q3 2024
Q3/YTD 2024 RESULTS Sales and Adjusted EBITDA: YTD/Q3 2024 Growth € million YTD 2024 YTD 2023 Q3 2024 Q3 2023 YTD Sales - Functional Ingredients 751.3 769.8 254.1 250.3 -2.4% & Solutions - Health & Nutrition 221.6 182.5 81.7 60.3 +21.4% Total Net Sales 972.9 952.3 335.8 310.6 +2.2% Adjusted EBITDA -
Slide 4: Sales growth per segment: YTD/Q3 2024
Q3/YTD 2024 RESULTS Sales growth per segment: YTD/Q3 2024 Sales growth Acquisitions/ Total Volume/Mix Price Organic Currency (Continued Operations) (Divestments) growth YTD 2024 vs YTD 2023 - Functional Ingredients & 3.1% -5.1% -2.0% -0.9% 0.5% -2.4% Solutions - Health & Nutrition 18.6% 3.2% 21.8% -
Slide 5: Functional Ingredients & Solutions
Q3/YTD 2024 RESULTS Functional Ingredients & Solutions Organic Sales growth of -2.0% Volume/Mix - Functional Ingredient & Solutions Q3 +7.1 • Volume/mix +3.1% (Q3: +7.1%) • Continuation of positive volume momentum in our Food segment • Softness in some markets, like semiconductors and agro-chemicals
Slide 6: Health & Nutrition
Q3/YTD 2024 RESULTS Health & Nutrition Q3 Organic Sales growth of +21.8% Volume/Mix - Health & Nutrition +27.8% • All three segments within Health & Nutrition (i.e., Nutrition, Pharma, and Biomedical Polymers) grew sales by double-digit percent vs Q3 2023, mainly due to volume/mix • Positive momentu
Slide 7: TotalEnergies Corbion Joint Venture
Q3/YTD 2024 RESULTS TotalEnergies Corbion Joint Venture Q3 +18.2% Organic Sales growth of 15.5% Sales - TotalEnergies Corbion • Continuous recovery of volume • Robust long term PLA drivers remain Adjusted EBITDA margin 11.0% (-340bps vs LY) • Adjusted EBITDA margin in line with 2024 estimate Q1'23 Q
Slide 8: Upgrade of FY 2024 outlook
Q3/YTD 2024 RESULTS Upgrade of FY 2024 outlook Organic sales growth: • Volume/mix growth: >5% • Pricing: Low-single-digit-negative pricing following input cost Previous guidance Updated guidance relaxation Updated guidance (July 2024) (Oct 2024) Organic growth (cont. operations) Adjusted EBITDA orga
Slide 9: Annex
Q3/YTD 2024 RESULTS Annex 9 29/10/2024
Slide 10: Restatements - Continued Operations
Q3/YTD 2024 RESULTS Restatements - Continued Operations Continued Operations Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 Q1 2024 Q2 2024 Q3 2024 € million Sales - Functi ona l Ingredi ents & Sol uti ons 258.4 261.1 250.3 248.9 1,018.7 239.3 257.9 254.1 - Hea l th & Nutri ti on 54.1 68.1 60.3 62.8 245.3
Slide 11: Investor relations
Investor relations alex.sokolowski@corbion.com www.corbion.com +31 20 590 6341